Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. Nov-Dec 2018;70(6):911-914.
doi: 10.1016/j.ihj.2018.06.006. Epub 2018 Aug 22.

A Critical Analysis of the COMPASS Trial With Respect to Benefit-Risk Assessment Using the Numbers Needed to Treat: Applicability and Relevance in Indian Patients With Stable Cardiovascular Disease

Affiliations
Free PMC article
Review

A Critical Analysis of the COMPASS Trial With Respect to Benefit-Risk Assessment Using the Numbers Needed to Treat: Applicability and Relevance in Indian Patients With Stable Cardiovascular Disease

P Kerkar et al. Indian Heart J. .
Free PMC article

Abstract

The recently published Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial evaluated the hypothesis that rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary prevention. In India, stable cardiovascular disease occurs in a much younger age group relative to the rest of the world. Our critical analysis of COMPASS trial showed that the younger age group appeared to derive greater benefit from the rivaroxaban+aspirin combination (relative to aspirin alone) as seen with number needed to treat metrics as compared to the older age group.

Keywords: Likelihood of being helped and harmed; Rivaroxaban; Stable Coronary artery disease; Young Indian Population.

Similar articles

See all similar articles

References

    1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202439slbl.pdf, (Last accessed on 6th March, 2018).
    1. Eriksson B.I., Borris L.C., Friedman R.J. Rivaroxaban versusenoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765–2775. - PubMed
    1. Lassen M.R., Ageno W., Borris L.C. Rivaroxaban versusenoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776–2786. - PubMed
    1. Buller H.R., Lensing A.W.A., Prins M.H. A dose-ranging study evaluating once-daily oral administrationof the factor Xa inhibitor rivaroxaban in the treatment ofpatients with acute symptomatic deep vein thrombosis: the einstein-DVT dose-ranging study. Blood. 2008;112(6):2242–2247. - PubMed
    1. The EINSTEIN Investigators Oral rivaroxaban for symptomaticvenous thromboembolism. N Engl J Med. 2010;363(26):2499–2510. - PubMed

MeSH terms

Substances

Feedback